Spots Global Cancer Trial Database for rimiducid
Every month we try and update this database with for rimiducid cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC) | NCT04249947 | Prostatic Neopl... Neoplasms by Hi... Neoplasms, Pros... Prostate Cancer Metastatic Cast... Neoplasms Prostatic Neopl... Genital Neoplas... Urogenital Neop... Neoplasms by Si... Prostatic Disea... Salivary Gland ... Salivary Gland ... Adenoid Cystic ... Salivary Duct C... Mucoepidermoid ... Acinic Cell Tum... | P-PSMA-101 CAR-... Rimiducid | 18 Years - | Poseida Therapeutics, Inc. | |
| P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM) | NCT03288493 | Multiple Myelom... | P-BCMA-101 CAR-... Rimiducid | 18 Years - | Poseida Therapeutics, Inc. | |
| Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study | NCT03733249 | Acute Lymphobla... Leukemia, Acute... Lymphoma, Non-H... Myelodysplastic... Primary Immunod... Anemia, Aplasti... Hemoglobinopath... Cytopenia Fanconi Anemia Diamond Blackfa... Thalassemia Anemia, Sickle ... | Rimiducid rivogenlecleuce... | 1 Month - 18 Years | Bellicum Pharmaceuticals | |
| Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant | NCT02065869 | Acute Lymphobla... Leukemia, Acute... Lymphoma, Non-H... Myelodysplastic... Primary Immunod... Anemia, Aplasti... Osteopetrosis Hemoglobinopath... Cytopenia Fanconi Anemia Diamond Blackfa... Thalassemia Anemia, Sickle ... | BPX-501 T cells Rimiducid | 1 Month - 18 Years | Bellicum Pharmaceuticals | |
| Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant | NCT02065869 | Acute Lymphobla... Leukemia, Acute... Lymphoma, Non-H... Myelodysplastic... Primary Immunod... Anemia, Aplasti... Osteopetrosis Hemoglobinopath... Cytopenia Fanconi Anemia Diamond Blackfa... Thalassemia Anemia, Sickle ... | BPX-501 T cells Rimiducid | 1 Month - 18 Years | Bellicum Pharmaceuticals | |
| P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma | NCT04960579 | Multiple Myelom... | P-BCMA-ALLO1 CA... Rimiducid | 18 Years - | Poseida Therapeutics, Inc. | |
| T-cells Expressing an Anti-SLAMF7 CAR for Treating Multiple Myeloma | NCT03958656 | Myeloma-Multipl... Myeloma, Plasma... | Cyclophosphamid... Fludarabine Rimiducid Anti-Signaling ... | 18 Years - 73 Years | National Institutes of Health Clinical Center (CC) | |
| Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study | NCT03733249 | Acute Lymphobla... Leukemia, Acute... Lymphoma, Non-H... Myelodysplastic... Primary Immunod... Anemia, Aplasti... Hemoglobinopath... Cytopenia Fanconi Anemia Diamond Blackfa... Thalassemia Anemia, Sickle ... | Rimiducid rivogenlecleuce... | 1 Month - 18 Years | Bellicum Pharmaceuticals | |
| P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors | NCT05239143 | Breast Cancer Ovarian Cancer Non Small Cell ... Colorectal Canc... Pancreatic Canc... Renal Cell Carc... Nasopharyngeal ... Head and Neck S... Gastric Cancer | P-MUC1C-ALLO1 C... Rimiducid | 18 Years - | Poseida Therapeutics, Inc. | |
| Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma | NCT02743611 | Acute Myeloid L... Myelodysplastic... Uveal Melanoma | BPX-701 Rimiducid | 18 Years - | Bellicum Pharmaceuticals | |
| Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma | NCT03721068 | Neuroblastoma Osteosarcoma | iC9.GD2.CAR.IL-... Cyclophosphamid... Fludarabine | 18 Months - | UNC Lineberger Comprehensive Cancer Center | |
| Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT | NCT02786485 | Leukemia Myelodysplastic... Lymphomas Multiple Myelom... Other High-risk... | rivogenlecleuce... Rimiducid | 18 Years - 65 Years | Bellicum Pharmaceuticals | |
| Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma | NCT03696784 | Lymphoma Lymphoma, B-Cel... Immune System D... Immunoprolifera... Lymphatic Disea... | iC9-CAR19 T cel... Bendamustine Fludarabine AP1903 Cyclophosphamid... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma | NCT03696784 | Lymphoma Lymphoma, B-Cel... Immune System D... Immunoprolifera... Lymphatic Disea... | iC9-CAR19 T cel... Bendamustine Fludarabine AP1903 Cyclophosphamid... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors | NCT05239143 | Breast Cancer Ovarian Cancer Non Small Cell ... Colorectal Canc... Pancreatic Canc... Renal Cell Carc... Nasopharyngeal ... Head and Neck S... Gastric Cancer | P-MUC1C-ALLO1 C... Rimiducid | 18 Years - | Poseida Therapeutics, Inc. | |
| Safety/PK Study of Gene Modified Donor T Cell Infusion in Children With Recurrent Hem Malignancies After Allo Transplant | NCT03459170 | Hematologic Mal... | BPX-501 T cells rimiducid | 1 Year - 18 Years | Bellicum Pharmaceuticals | |
| Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL | NCT03016377 | Acute Lymphobla... Immune System D... Immunoprolifera... | iC9-CAR19 cells Rimiducid Cyclophosphamid... Fludarabine | 3 Years - 70 Years | UNC Lineberger Comprehensive Cancer Center | |
| Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant | NCT02065869 | Acute Lymphobla... Leukemia, Acute... Lymphoma, Non-H... Myelodysplastic... Primary Immunod... Anemia, Aplasti... Osteopetrosis Hemoglobinopath... Cytopenia Fanconi Anemia Diamond Blackfa... Thalassemia Anemia, Sickle ... | BPX-501 T cells Rimiducid | 1 Month - 18 Years | Bellicum Pharmaceuticals | |
| Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma | NCT03721068 | Neuroblastoma Osteosarcoma | iC9.GD2.CAR.IL-... Cyclophosphamid... Fludarabine | 18 Months - | UNC Lineberger Comprehensive Cancer Center | |
| P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies | NCT06014762 | Diffuse Large B... Follicular Lymp... Mantle Cell Lym... Marginal Zone L... Primary Mediast... Chronic Lymphoc... | P-CD19CD20-ALLO... Rimiducid | 18 Years - | Poseida Therapeutics, Inc. | |
| Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant | NCT01744223 | Acute Lymphobla... Acute Myelogeno... Lymphoma Myelodysplastic... | BPX-501 dose 1 Rimiducid BPX-501 dose 2 BPX-501 dose 3 BPX-501 dose 4 SCT | 18 Years - 65 Years | Bellicum Pharmaceuticals | |
| Safety/PK Study of Gene Modified Donor T Cell Infusion in Children With Recurrent Hem Malignancies After Allo Transplant | NCT03459170 | Hematologic Mal... | BPX-501 T cells rimiducid | 1 Year - 18 Years | Bellicum Pharmaceuticals | |
| Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant | NCT02477878 | Leukemia Myelodysplastic... Lymphoma Multiple Myelom... Hematologic Neo... | BPX-501 Rimiducid | 18 Years - 65 Years | Bellicum Pharmaceuticals | |
| P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies | NCT06014762 | Diffuse Large B... Follicular Lymp... Mantle Cell Lym... Marginal Zone L... Primary Mediast... Chronic Lymphoc... | P-CD19CD20-ALLO... Rimiducid | 18 Years - | Poseida Therapeutics, Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
